Jiangsu Recbio Technology Co., Ltd.
HKSE: 2179.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Yong Liu
- Employees
- 531
- Headquarters
- Taizhou, China
- IPO year
- 2022
- Market cap
- HK$2.7B
- Website
- https://www.recbio.cn
Loading 2179…
Loading profile data…Frequently asked questions about 2179
What does Jiangsu Recbio Technology Co., Ltd. (2179.HK) do?
Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China. The company is developing vaccines for the treatment of cervical cancer and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is i...
Where does 2179.HK trade?
Jiangsu Recbio Technology Co., Ltd. (2179.HK) trades on the Hong Kong Stock Exchange.
What sector is 2179.HK in?
Jiangsu Recbio Technology Co., Ltd. (2179.HK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Jiangsu Recbio Technology Co., Ltd.?
Yong Liu is the chief executive officer of Jiangsu Recbio Technology Co., Ltd. (2179.HK).
Where is Jiangsu Recbio Technology Co., Ltd. headquartered?
Jiangsu Recbio Technology Co., Ltd. is headquartered in China.
Does 2179.HK pay a dividend?
Jiangsu Recbio Technology Co., Ltd. (2179.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 2179.HK go public?
Jiangsu Recbio Technology Co., Ltd. (2179.HK) completed its initial public offering in 2022.